Anti Retroviral Therapy in Early Stage Show Excess Benefits

Study results announced today by the HIV Prevention Trials Network (HPTN) show excess advantages and benefits of early antiretroviral therapy (ART) in HIV clinical consequences. Stretched research of HPTN 052 study facts introduced today at the XIX International AIDS Conference in Washington, D.C. confirmed that early versus scheduled ART confirmed a trend toward delay the ideal time to actually both AIDS and non-AIDS major activities and substantially delayed the ideal time to AIDS events, death and tuberculosis.

The complete incidence of clinical activities appeared to be substantially lower in individuals handled in the early therapy arm. The brand new findings demonstrate that immediate ART substantially diminished the likelihood of clinical events likely due to reversal of immune reduction.

Commenting upon the findings, Myron Cohen, MD, Co-Principal Investigator of HPTN, and of course the HPTN 052 Protocol Chair said: "Each of these new breakthroughs provides further affirmation related to health benefits of earlier antiretroviral therapy. The mutual avoidance and therapy advantages and benefits of antiretroviral procedures make broader assessments and treatment urgent and imperative."